Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05515601 · ClinicalTrials.gov registry record · Phase 1
A Bioequivalence Study of Mirikizumab (LY3074828) in Healthy Participants
A Phase 1 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 396
- Enrollment target
NCT05515601 is a Phase 1 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 396 participants.
The verdict
NCT05515601, a Phase 1 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 396 participants
- Enrollment target
Study Summary
The main purpose of this study is to evaluate amount of mirikizumab (test) that gets into the blood stream and how long it takes the body to get rid of it, when given via autoinjector compared to mirikizumab (reference) solution given via autoinjector. The information about any adverse effects experienced will be collected and the tolerability of mirikizumab will also be evaluated. Screening is required within 35 days prior to enrolment. For each participant, the total duration of the clinical trial will be about 17 weeks including screening.
Interventions
- DRUG Mirikizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 396 participants |
| Start Date | 2022-08-31 |
| Est. Completion | 2023-02-20 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05515601
The ClinicalTrials.gov registry entry for NCT05515601 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 396 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Mirikizumab is the first listed.
NCT05515601 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05515601 about?
NCT05515601 is a clinical study titled "A Bioequivalence Study of Mirikizumab (LY3074828) in Healthy Participants". The main purpose of this study is to evaluate amount of mirikizumab (test) that gets into the blood stream and how long it takes the body to get rid of it, when given via autoinjector compared to mirikizumab (reference) solution given via autoinjector. The information about any adverse effects exper...
What is the current status of trial NCT05515601?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 396 participants. The study started on 2022-08-31. Estimated completion is 2023-02-20.
What interventions are being tested in trial NCT05515601?
The interventions under investigation include: Mirikizumab (DRUG).
Who is sponsoring clinical trial NCT05515601?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.